Gilead 7977 and BMS 790052 fit that bill but they aren't partners anymore. I know they are each trying to develop similar drugs to go with their own. I hope they are successful. There are also many other companies trying to meet those requirements. Good luck to all of them.
mallani said
Dec 24, 2012
We are looking for a treatment combination that will do the following:
1. Achieve close to 100% SVR rate in all Genotypes and subgroups
2. Be effective in all treatment groups, including age, sex, ethnicity, fibrosis stage and previous treatment history.
3. Be interferon-free and possibly ribavirin-free.
4. Have a short treatment duration, ideally no more than 12 weeks ( 24 weeks for F4's)
5. Have a simple pill load, combining active drugs, with one-two pills/ day.
6. Have no significant side effects.
7. Be available to all patients.
None of the drug combos currently being tested will come close to achieving these. Just as Incivek and Victrelis were Step 1 towards Rx, these drugs will be Step 2. Step 3 and even 4 may be required. PLEASE DEVELOP A VACCINE???
mallani said
Dec 23, 2012
Hi Jim, I agree the GS combo shows the most promise. However, as daclatasvir has been replaced by GS-5885, there is a question mark. The NS5A inhibitors seem to show differing potency, and GS-5885 may not be as effective. If Ribavirin is used, there will be significant anaemia. From what I have seen, the geno 1a's may need Riba +/- Peg. to get satisfactory SVR's. The sheer volume of data that will be presented to the FDA in 2 years time is mindblowing.
-- Edited by mallani on Monday 24th of December 2012 05:31:54 AM
We are looking for a treatment combination that will do the following:
1. Achieve close to 100% SVR rate in all Genotypes and subgroups
2. Be effective in all treatment groups, including age, sex, ethnicity, fibrosis stage and previous treatment history.
3. Be interferon-free and possibly ribavirin-free.
4. Have a short treatment duration, ideally no more than 12 weeks ( 24 weeks for F4's)
5. Have a simple pill load, combining active drugs, with one-two pills/ day.
6. Have no significant side effects.
7. Be available to all patients.
None of the drug combos currently being tested will come close to achieving these. Just as Incivek and Victrelis were Step 1 towards Rx, these drugs will be Step 2. Step 3 and even 4 may be required. PLEASE DEVELOP A VACCINE???
Hi Jim, I agree the GS combo shows the most promise. However, as daclatasvir has been replaced by GS-5885, there is a question mark. The NS5A inhibitors seem to show differing potency, and GS-5885 may not be as effective. If Ribavirin is used, there will be significant anaemia. From what I have seen, the geno 1a's may need Riba +/- Peg. to get satisfactory SVR's. The sheer volume of data that will be presented to the FDA in 2 years time is mindblowing.
-- Edited by mallani on Monday 24th of December 2012 05:31:54 AM